文献速递冠心病外科

CytoSorb吸附器在紧急非体外循环冠脉搭桥术前清除替格瑞洛与利伐沙班

Ticagrelor and Rivaroxaban Elimination With CytoSorb Adsorber Before Urgent Off-Pump Coronary Bypass.
PubMed 文献 · Ann Thorac Surg · 2020-05-11

本文报道一例58岁男性,因冠脉疾病接受替格瑞洛、因房颤接受利伐沙班治疗,在紧急非体外循环冠脉搭桥术前使用CytoSorb血液吸附清除凝血活性药物。患者术中及术后经过平稳,出血控制充分。该病例提示此方法在管理抗血小板及抗凝药物方面具有前景。

要点

  • 紧急非体外循环冠脉搭桥术前可用CytoSorb血液吸附清除替格瑞洛和利伐沙班。
  • 本例患者术中及术后经过平稳,出血控制充分。
  • 该病例提示CytoSorb吸附是管理抗血小板/抗凝药物的一种有前景的方法。

核心结论

  • 紧急非体外循环冠脉搭桥术前使用CytoSorb血液吸附清除替格瑞洛和利伐沙班,本例患者术中及术后经过平稳,出血控制充分。

研究设计与样本

  • 单病例报告:58岁男性,因冠脉疾病接受替格瑞洛治疗、因房颤接受利伐沙班治疗,在紧急非体外循环冠脉搭桥术前进行CytoSorb血液吸附。

主要发现

  • 患者术中及术后经过平稳,出血控制充分。

临床怎么用

  • 对于正在使用替格瑞洛和利伐沙班且需紧急非体外循环冠脉搭桥的高出血风险患者,可考虑术前使用CytoSorb血液吸附清除凝血活性药物。

局限性

  • 单病例报告,结论的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CytoSorb hemoadsorption (CytoSorbents Inc, Monmouth Junction, NJ) was performed shortly before an urgent off-pump coronary artery bypass operation in a 58-year-old man at high risk of bleeding as a result of treatment of coronary artery disease with ticagrelor and treatment of atrial fibrillation with rivaroxaban. The patient experienced dissection of the left anterior descending artery during a percutaneous coronary intervention. Preoperatively, CytoSorb hemoadsorption was applied to eliminate the coagulative active medications. His intraoperative and postoperative courses were uneventful, with adequate bleeding control. This case highlights a promising approach for managing antiplatelet drugs and anticoagulant agents such as ticagrelor and rivaroxaban before off-pump coronary artery bypass.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mair H, Jilek C, Haas B, et al. Ticagrelor and Rivaroxaban Elimination With CytoSorb Adsorber Before Urgent Off-Pump Coronary Bypass. Ann Thorac Surg. 2020. PMID: 32407851. doi:10.1016/j.athoracsur.2020.03.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。